ATE432263T1 - Imidazol-4-ylmethanol-derivate zur verwendung als steroid c17-20 lyase-hemmer - Google Patents
Imidazol-4-ylmethanol-derivate zur verwendung als steroid c17-20 lyase-hemmerInfo
- Publication number
- ATE432263T1 ATE432263T1 AT00969903T AT00969903T ATE432263T1 AT E432263 T1 ATE432263 T1 AT E432263T1 AT 00969903 T AT00969903 T AT 00969903T AT 00969903 T AT00969903 T AT 00969903T AT E432263 T1 ATE432263 T1 AT E432263T1
- Authority
- AT
- Austria
- Prior art keywords
- ylmethanol
- steroid
- imidazole
- derivatives
- tumors
- Prior art date
Links
- QDYTUZCWBJRHKK-UHFFFAOYSA-N imidazole-4-methanol Chemical class OCC1=CNC=N1 QDYTUZCWBJRHKK-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002697 lyase inhibitor Substances 0.000 title 1
- 150000003431 steroids Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000004384 Alopecia Diseases 0.000 abstract 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- 206010020112 Hirsutism Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
- 206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
- 206010047486 Virilism Diseases 0.000 abstract 1
- 208000030270 breast disease Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 abstract 1
- 208000006155 precocious puberty Diseases 0.000 abstract 1
- 201000004240 prostatic hypertrophy Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP30155699 | 1999-10-22 | ||
| JP2000189728 | 2000-06-20 | ||
| PCT/JP2000/007283 WO2001030762A1 (en) | 1999-10-22 | 2000-10-19 | Imidazol-4-ylmethanols use as inhibitors of steroid c17-20 lyase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE432263T1 true ATE432263T1 (de) | 2009-06-15 |
Family
ID=26562739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00969903T ATE432263T1 (de) | 1999-10-22 | 2000-10-19 | Imidazol-4-ylmethanol-derivate zur verwendung als steroid c17-20 lyase-hemmer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6649643B1 (de) |
| EP (1) | EP1222174B1 (de) |
| AT (1) | ATE432263T1 (de) |
| AU (1) | AU7950000A (de) |
| CA (1) | CA2387869A1 (de) |
| CO (1) | CO5251418A1 (de) |
| DE (1) | DE60042274D1 (de) |
| PE (1) | PE20010781A1 (de) |
| WO (1) | WO2001030762A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2429133C (en) * | 2000-11-17 | 2009-08-18 | Takeda Chemical Industries, Ltd. | Novel imidazole derivatives, production method thereof and use thereof |
| DE60144246D1 (de) * | 2000-11-20 | 2011-04-28 | Takeda Pharmaceutical | Imidazolderivate, verfahren zu deren herstellung und deren verwendung |
| CN1819996B (zh) * | 2003-07-10 | 2010-10-27 | Osi制药公司 | 作为细胞色素p450抑制剂的亚萘基衍生物 |
| US7662844B2 (en) | 2004-07-12 | 2010-02-16 | Osi Pharmaceuticals, Inc. | Naphthylene derivatives as cytochrome P450 inhibitors |
| JP2009524616A (ja) * | 2006-01-27 | 2009-07-02 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｎｓ疾患のための４−イミダゾール誘導体の使用 |
| MX2009003801A (es) | 2006-10-19 | 2009-04-22 | Hoffmann La Roche | Aminometil-4-imidazoles. |
| BRPI0718054A2 (pt) | 2006-11-02 | 2013-11-05 | Hoffmann La Roche | 2-imidazóis substituídos como moduladores de receptores associados à traços de aminas |
| AU2007321376A1 (en) | 2006-11-16 | 2008-05-22 | F. Hoffmann-La Roche Ag | Substituted 4-imidazoles |
| WO2008071574A1 (en) | 2006-12-13 | 2008-06-19 | F. Hoffmann-La Roche Ag | Novel 2 -imidazoles as ligands for trace amine associated receptors (taar) |
| US20080146523A1 (en) | 2006-12-18 | 2008-06-19 | Guido Galley | Imidazole derivatives |
| CA2675221C (en) | 2007-02-02 | 2016-02-23 | F. Hoffmann-La Roche Ag | Novel 2-aminooxazolines as taar1 ligands |
| MX2009008465A (es) | 2007-02-15 | 2009-08-20 | Hoffmann La Roche | Nuevas 2-aminooxazolinas como ligandos de taar1. |
| CA2691082A1 (en) | 2007-07-02 | 2009-01-08 | F. Hoffmann-La Roche Ag | 2 -imidazolines having a good affinity to the trace amine associated receptors (taars) |
| BRPI0812833A2 (pt) | 2007-07-03 | 2014-12-09 | Hoffmann La Roche | 4-imidazolinas e seu uso como antidepressivos |
| KR101133862B1 (ko) | 2007-07-27 | 2012-04-06 | 에프. 호프만-라 로슈 아게 | Ｔａａｒ 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민 |
| CA2695331A1 (en) | 2007-08-03 | 2009-02-12 | F. Hoffmann-La Roche Ag | Pyridinecarboxamide and benzamide derivatives as taar1 ligands |
| US20100261689A1 (en) * | 2007-10-29 | 2010-10-14 | Masuo Yamaoka | Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies |
| US8242153B2 (en) | 2008-07-24 | 2012-08-14 | Hoffmann-La Roche Inc. | 4,5-dihydro-oxazol-2YL derivatives |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| CA2838971C (en) | 2011-06-15 | 2019-07-30 | Takeda Pharmaceutical Company Limited | Production method of imidazole derivatives |
| RS60825B1 (sr) | 2016-03-17 | 2020-10-30 | Hoffmann La Roche | Aktivnost derivata 5-etiol-4-metil-pirazol-3-karboksamida kao agonista taar-a |
| CN105884691B (zh) * | 2016-06-02 | 2017-08-25 | 江苏恒瑞医药股份有限公司 | 一种制备右美托咪定及其中间体的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA854400B (en) * | 1984-06-18 | 1987-02-25 | Lilly Co Eli | 4(5)-substituted imidazoles |
| CA2229000C (en) * | 1991-02-21 | 2002-04-09 | Sankyo Company, Limited | 1-biphenylimidazole derivatives, their preparation and their therapeutic use |
| EP0721943A4 (de) | 1993-09-30 | 1996-09-04 | Yamanouchi Pharma Co Ltd | Azol-derivate und pharmazeutische präparate |
| NZ302392A (en) * | 1995-03-01 | 1998-08-26 | Yamanouchi Pharma Co Ltd | Tricyclic substituted imidazole derivatives and medicaments thereof |
| US6573289B1 (en) | 1998-04-23 | 2003-06-03 | Takeda Chemical Industries, Ltd. | Naphthalene derivatives, their production and use |
| EP1193258A4 (de) | 1999-06-22 | 2002-11-13 | Takeda Chemical Industries Ltd | Verfahren zur herstellung von imidazolderivaten |
| US6800778B1 (en) | 1999-10-22 | 2004-10-05 | Takeda Chemical Industries, Ltd. | Process for producing optically active naphthalene derivative and optical resolver therefor |
-
2000
- 2000-10-18 PE PE2000001110A patent/PE20010781A1/es not_active Application Discontinuation
- 2000-10-19 CA CA002387869A patent/CA2387869A1/en not_active Abandoned
- 2000-10-19 AU AU79500/00A patent/AU7950000A/en not_active Abandoned
- 2000-10-19 EP EP00969903A patent/EP1222174B1/de not_active Expired - Lifetime
- 2000-10-19 DE DE60042274T patent/DE60042274D1/de not_active Expired - Lifetime
- 2000-10-19 US US10/110,599 patent/US6649643B1/en not_active Expired - Lifetime
- 2000-10-19 AT AT00969903T patent/ATE432263T1/de not_active IP Right Cessation
- 2000-10-19 WO PCT/JP2000/007283 patent/WO2001030762A1/en not_active Ceased
- 2000-10-20 CO CO00080138A patent/CO5251418A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| DE60042274D1 (de) | 2009-07-09 |
| EP1222174B1 (de) | 2009-05-27 |
| EP1222174A1 (de) | 2002-07-17 |
| AU7950000A (en) | 2001-05-08 |
| US6649643B1 (en) | 2003-11-18 |
| CA2387869A1 (en) | 2001-05-03 |
| WO2001030762A1 (en) | 2001-05-03 |
| PE20010781A1 (es) | 2001-08-08 |
| CO5251418A1 (es) | 2003-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60042274D1 (de) | Imidazol-4-ylmethanol-derivate zur verwendung als steroid c17-20 lyase-hemmer | |
| DE69928697D1 (de) | Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren | |
| AU2002340010A1 (en) | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | |
| MY136097A (en) | Methods for treating osteoarthritis using an estrogen agonist/antagonist | |
| WO2002022576A3 (en) | 3-substituted indole carbohydrazides useful as cell proliferation and angiogenesis inhibitors | |
| WO2002030462A3 (en) | Hedgehog antagonists, methods and uses related thereto | |
| DE60226271D1 (de) | Verfahren zum nachweis von prostatakrebs | |
| ATE328874T1 (de) | Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren | |
| GEP20074122B (en) | Treating benign prostate hyperplasia with selective androgen receptor modulators | |
| GB2399420A (en) | Objective oriented NMR logging method and apparatus | |
| TR199900556T2 (xx) | Prostat hipertrofisini ve prostat kanserini tedavi etmek i�in vas�ta. | |
| RU94046057A (ru) | Ингибиторы активности тестостерон 5 альфа -редуктазы, фармкомпозиция, способ подавления активности, тестостерон 5 альфа -редуктазы | |
| NO961575L (no) | 16-substituerte-4-aza-androstan 5-reduktase-isoenzym 1-inhibitorer | |
| ATE129013T1 (de) | Steroid 5-alpha-reduktase. | |
| ATE312445T1 (de) | Verfahren und system zum verarbeiten von informationen in einem elektronischen gerät | |
| DK1411916T3 (da) | Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd | |
| DE69417248D1 (de) | Delta 16 ungesättigtes c17 heterocyclische steroide zur verwendung als steroid c17-20 lyase inhibitoren | |
| TR200402566T2 (tr) | Bitki transformasyon yöntemleri. | |
| DE69703201D1 (de) | Hydroxyamidinderivate verwendbar als stickoxidsynthese inhibitoren | |
| DE69417925D1 (de) | 7-substituierte-4-aza-steroid-derivate als 5-alpha-reductase-hemmer | |
| MXPA04005417A (es) | Uso de antagonista de h1 y un esteroide seguro para el tratamiento de la rinitis. | |
| WO2003073821A3 (en) | Shc PROTEIN-RELATED METHODS AND COMPOSITIONS FOR THE PROGNOSIS OF BREAST, PROSTATE AND OVARIAN CANCER | |
| NO20031745L (no) | Inhibisjon av vekstfaktoravhengigheten til tumorceller | |
| ATE223928T1 (de) | Azole peptidomimetische verbindungen als thrombin rezeptor antagoniste | |
| DE60143023D1 (de) | Tumorhemmende nitroacridin-zusammensetzungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |